DrugInformer Search

Liquamar

Ingredients: Phenprocoumon
Average User Review Score
* Based on 0 reviews from across the web.
Wikipedia

Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.

Read more on Wikipedia
Share

  Please use Workbench for in-depth research on Liquamar.

Common adverse events from online conversations
Common adverse events from FDA database
* Extracted from FDA Adverse Event Reports for all drugs with the same active ingredients.

Tell us about your Experience with Liquamar

Thank you for sharing your experience with us!

Share Your Experience

Druginformer Identified Side Effects: None

Posted By Anonymous in facebook.com on January 30, 2010 @ 12:00 am

Azadixwaz Glucosamine What is it? Glucosamine is a dietary supplement used to treat arthritis (osteoarthritis). Other names for Glucosamine include: Chitosamine and Glucosamine sulfate. Ask you...


* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.